NIH PAR · NCI · R21
PAR-25-244: Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
This Notice of Funding Opportunity (NOFO) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants will support innovative studies designed to investigate biological/genetic bases of cancer health disparities, such as (1) mechanistic studies of biological factors associated with cancer health disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This NOFO is also designed to aid and facilitate the growth…
- NOFO number
- PAR-25-244
- Type
- PAR
- Activity code
- R21
- Primary institute
- NCI · National Cancer Institute
- Clinical trials
- Not Allowed
- Posted
- Nov 18, 2024
- Opens
- Jan 16, 2025
- Expires
- Nov 17, 2027
PAR-25-244 due dates
4 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| February 16, 2025 | March 16, 2025 * | Not Applicable | July 2025 | October 2025 | December 2025 |
| June 16, 2025 | July 16, 2025 * | Not Applicable | November 2025 | January 2026 | April 2026 |
| October 16, 2025 | November 16, 2025 * | Not Applicable | March 2026 | May 2026 | July 2026 |
| February 16, 2026 | March 16, 2026 * | Not Applicable | July 2026 | October 2026 | December 2026 |
| June 16, 2026 | July 16, 2026 * | Not Applicable | November 2026 | January 2027 | April 2027 |
| October 16, 2026 | November 16, 2026 * | Not Applicable | March 2027 | May 2027 | July 2027 |
| February 16, 2027 | March 16, 2027 * | Not Applicable | July 2027 | October 2027 | December 2027 |
| June 16, 2027 | July 16, 2027 * | Not Applicable | November 2027 | January 2028 | April 2028 |
| October 16, 2027 | November 16, 2027 * | Not Applicable | March 2028 | May 2028 | July 2028 |
Projects funded under PAR-25-244
NIH RePORTER lists 3 projects funded under PAR-25-244 in FY2022–FY2026, with $1.3M in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
3
Distinct projects, FY2022–FY2026
New awards
3
Type 1 (new project) award records
NIH funding
$1.3M
Award dollars under PAR-25-244, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 3 | 3 | $1.3M |
Institutions with the most funding
- University of Tx MD Anderson Can Ctr$427K · 1 project
- University of Illinois at Chicago$423K · 1 project
- Cleveland Clinic Lerner Com-Cwru$404K · 1 project
Funding institutes
- NCI$1.3M · 3
Activity codes funded
- R213 records
Most recent new awards
- Unraveling the Interplay: Microbiome, p16 Expression, High-Risk HPV Infection, and Clinical Outcomes in Penile Cancer Across Diverse Patient Cohorts with Varied Mortality and Incidence Profiles (opens NIH RePORTER)
University of Tx MD Anderson Can Ctr · 1R21CA299578-01A1 · NCI · Notice Jul 30, 2026
$427KR21
- Disparities in AML treatment (opens NIH RePORTER)
University of Illinois at Chicago · 1R21CA303745-01A1 · NCI · Notice May 26, 2026
$423KR21
- Discerning the role of CDK10 in driving aggressiveness and disparities of triple negative breast cancer (opens NIH RePORTER)
Cleveland Clinic Lerner Com-Cwru · 1R21CA309627-01 · NCI · Notice Apr 7, 2026
$404KR21
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-25-244. Contact the program officer at the institute that fits your research before applying.
- NCI · National Cancer Institute
- none
Related notices
Mar 31, 2025 · NOT-OD-24-084
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.
Award terms
- Application types allowed
- NewResubmission The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- The combined budget for direct costs for the two year project period may not exceed 275,000. No more than 200,000 may be requested in any single year.
- Project period
- The total project period may not exceed 2 years.  NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-24-291.
- Companion NOFOs: PAR-25-243.
Other open NOFOs for R21
- PAR-25-346Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)NCI · next due Oct 16, 2026
- PAR-25-321Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)NCI · next due Oct 16, 2026
- PAR-25-070Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)NCI · next due Oct 16, 2026
- PA-25-253Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)NCI · next due Oct 16, 2026
- PAR-25-143Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)NCI · next due Oct 16, 2026
- PAR-25-044Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)NCI · next due Oct 16, 2026
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.